For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.
He first came into contact with the stock market and shares during his banking apprenticeship. After completing this in 2000, he gained his first journalistic experience in the editorial department of a financial portal. During his subsequent studies in business administration, he also worked in the area of investor relations.
Since then, he has remained true to the capital markets and is excited to report on every newly discovered interesting story - as well as on long-standing success stories.
Commented by Fabian Lorenz
Commented by Fabian Lorenz on January 24th, 2024 | 07:45 CET
More than 100% upside potential - Buy recommendations for BASF, Evotec and Saturn Oil + Gas
After the price slide of recent weeks, Evotec shares appear to be ripe for a countermovement. In a conference call, the Company attempted to provide clarification and seems to have convinced analysts. Expert opinions on BASF are divided. Has the bottom been reached after the preliminary figures? At least the dividend yield of 8% is attractive. Investors are also anticipating a high dividend from Saturn Oil & Gas soon. Analysts see more than 100% upside potential in the shares of the junior oil producer. The valuation is significantly lower than the peer group. The Canadian company will significantly reduce its debt in the current year, making the share increasingly attractive in terms of free cash flow and enterprise value. The latest drilling program has also produced strong results.
Read
Commented by Fabian Lorenz on January 18th, 2024 | 08:30 CET
Morphosys on the verge of a short squeeze? Evotec share drops like a stone! Almonty Industries is exciting!
Share price disaster at Evotec. The shares of the German biotech company are falling like a stone in 2024 and have already lost over 30% of their value in just a few trading days. This results from the CEO's surprising resignation and delayed reports of insider transactions. "Manager-Magazin" added fuel to the fire with an article. Morphosys, on the other hand, is taking off. The blood cancer drug Pelabresib is causing speculation and price swings. Could there even be a short squeeze? The Almonty Industries share is also exciting at the moment. The shares of the raw materials company, which focuses on tungsten, appear to have bottomed out and are starting an upward trend. Operationally, Almonty is facing exciting times. Analysts expect the tungsten producer to more than triple its turnover between 2023 and 2025. Given the expected profit in the coming year, the share is anything but expensive.
Read
Commented by Fabian Lorenz on January 17th, 2024 | 07:00 CET
Disaster at Plug Power! Opportunities with Thyssenkrupp Nucera and First Hydrogen shares!
The share price horror at hydrogen pioneers Nel and Plug Power continues in the new year. Yesterday alone, Plug Power's share price fell by more than 6% and has lost almost 30% of its value in just a few days of trading. Nel does not fare much better. Does this mean the comeback of hydrogen shares will fail in 2024? Investors should take a closer look at Plug Power; after all, the management itself has announced that it could run out of money. In terms of valuation and operational development, the two newcomers, First Hydrogen and Thyssekrupp Nucera, appear to be more attractive than the top dogs. Experts believe that First Hydrogen's shares, with their current market capitalization of CAD 80 million and further solid development in 2023, are currently on a special offer. And with Thyssenkrupp Nucera, analysts see around 90% upside potential.
Read
Commented by Fabian Lorenz on January 11th, 2024 | 07:00 CET
Evotec is in the analyst check, Tui with Wanderlust, and another 100% gain for Manuka Resources?
The Evotec stock is currently not for the faint-hearted. After the resignation of the long-serving board member caused uncertainty, the biotech company was able to reassure investors with a milestone payment. Analysts are speaking out and expressing their opinions, and a real "bull" is among them. And what about Manuka Resources? At the beginning of December, news about an exciting project for battery metals caused a jump in the share price. Is it now worth getting in after the consolidation? The Tui share has also recently consolidated after a 50% gain within a few weeks. Analysts' price targets for the tourism company's shares vary widely. Hold or buy?
Read
Commented by Fabian Lorenz on January 10th, 2024 | 07:30 CET
Bayer with a blockbuster! Vonovia weak! And how are Desert Gold shares doing?
While the DAX, Dow & Co. started the new year weakly, Bayer shares are holding up surprisingly well and can maintain the price gains from the end of 2023. The share price is being supported by positive news. A new blockbuster is waiting in the wings. Vonovia shares, on the other hand, are suffering from profit-taking, although analysts see further upside potential. Is concrete gold celebrating a comeback? And what about real gold? The price has weakened recently, but analysts believe USD 2,200 per ounce is possible, and central banks continue buying heavily. This should benefit not only the major gold producers but also low-cost explorers such as Desert Gold.
Read
Commented by Fabian Lorenz on January 4th, 2024 | 07:30 CET
Price rockets 2024? Bayer, Siemens Energy and dynaCERT
Analysts expect Siemens Energy shares to gain 50% in the new year. But have the problems from 2023 really been dealt with? There are doubters, and their price targets are significantly lower. Bayer has also had a challenging year. The share was one of the weakest DAX stocks in 2023. Will 2024 bring new momentum? At least 2023 ended with an important stage victory. But analysts remain skeptical. There are reasons for a pleasing share price performance in 2024 at dynaCERT. The hydrogen company has three hot irons in the fire and landed numerous orders in 2023. Sales should now pick up, and the share should break out of its sideways trend.
Read
Commented by Fabian Lorenz on January 3rd, 2024 | 07:20 CET
100% share price increase in a few days! Plug Power, BYD and Defense Metals shares
Within just a few days, the Defense Metals share price more than doubled shortly before Christmas. Even if the price level of the developer of a rare earths project in Canada could not be fully maintained, the share is entering 2024 with new momentum. Important data is due soon. If these are also positive, the current valuation of around CAD 50 million could be a real bargain. Plug Power is not a bargain despite the massive drop in the share price. The hydrogen specialist needs to grow and accelerate its path to break even. The e-commerce giant Amazon should help with this. BYD can only dream of doing big business in the US so far. The market is closed to Chinese e-car manufacturers. Is it justified?
Read
Commented by Fabian Lorenz on December 28th, 2023 | 07:30 CET
Morphosys with 50% risk? BioNTech and Defence Therapeutics share with positive news
Will the Morphosys share price halve? Analysts believe this is possible, although the German biotech veteran has been one of the winners in the sector this year. Overall, biotech shares were not among the favorites of investors in 2023. Nevertheless, the billion-dollar takeover of Karuna Therapeutics by Bristol-Myers Squibb announced yesterday gives the sector hope for a better performance in 2024. Today, we are focusing on three companies of different sizes, including Morphosys and Defence Therapeutics. The biotech company with a focus on immuno-oncology is closing the year with further positive news. The FDA has given the green light for the start of trials next year, which could open up a market worth billions. BioNTech has several pieces of positive news. Here, too, the FDA has made a positive statement, and the Company has achieved a milestone victory against CureVac.
Read
Commented by Fabian Lorenz on December 27th, 2023 | 07:30 CET
Christmas Surprises: Nel, CureVac, SMA Solar, Altech Advanced Materials
Far from a peaceful Christmas season, these stocks had some exciting news just before Christmas Eve: While SMA Solar had to fend off a short attack, CureVac lost the first round in the patent dispute with BioNTech over the COVID-19 vaccine. CureVac claims a share of the billions in profits for itself. Will CureVac now walk away empty-handed? In contrast, Altech Advanced Materials can pop the corks before New Year's Eve. The Company has reached another milestone on the road to revolutionizing battery technology. The feasibility study promises millions in profits. Nel can look forward to special earnings as a fine is significantly lower than expected.
Read
Commented by Fabian Lorenz on December 21st, 2023 | 07:10 CET
New share price horror at Bayer, price explosion at CropEnergies and GoviEx Uranium
CropEnergies shareholders were treated to a real treat yesterday, December 20. The share price rose by almost 70% to EUR 11.50. The parent company, Südzucker, wants to completely take over the biofuel producer. What do analysts say about the deal? Experts remain negative on Bayer. The Leverkusen-based company is one of the weakest DAX shares in 2023 and, according to analysts, could fall further to EUR 25. Are additional fines looming in the US? In contrast, the price of uranium is robust. The Climate Conference in Dubai once again confirmed that many countries worldwide are relying heavily on nuclear energy. The GoviEx Uranium share should benefit from this trend in the coming year. The capital requirement has been covered, and the share has a 30% upside potential in the initial phase.
Read